DISGENET Rebrand: A Fresh Look, Same Reliable Data for Tomorrow

News July 8, 2024

DISGENET — our gene-disease association knowledge platform — was created in 2010 driven by our mission that a greater understanding of human genetics was vital to improve people’s health. With over 100,000 web users, we see you agree. Today, that need for reliable, high-quality genomics data hasn’t faltered, but the way we access data has […]

DISGENET: The Next Chapter For Disease Genomics Research

Product June 19, 2024

From today, DisGeNET.org and DISGENET plus will become one unified platform found at disgenet.com. DisGeNET has become a cornerstone for bioinformatics research since starting in 2010. As a small team, we have dedicated 15 years to this valuable resource and we are committed to continuously improving the platform for you, our users. As you can imagine, […]

Anticipating Drug Toxicity: data-driven drug safety with DISGENET

Article September 12, 2023

Key points What is flupirtine? Flupirtine, an aminopyridine introduced in 1984 as a non-opioid analgesic for acute and chronic pain, embarked on a tumultuous journey within the medical landscape. Initially approved for broad pain management, its trajectory shifted in 2013 due to concerns over liver toxicity. The European Medicines Agency (EMA) limited its use to […]

Genetics for drug and chemical risk assessment

Article March 9, 2023

In recent years, there has been an increasing appreciation of the need to consider variability in human populations in evaluating health risks for new and existing chemicals. Recent policies such as The Frank R. Lautenberg Chemical Safety for the twenty-first Century Act (2016) require the US Environmental Protection Agency to evaluate new and existing toxic chemicals with explicit […]

Genetic support for FDA approvals in 2021

Article October 6, 2022

Key points Human genetics and FDA drug approvals in 2021 There is compelling evidence of the value of incorporating genetic information in the drug development process. A drug target supported by genetic evidence has a 2-fold higher probability of successful clinical development compared to those targets with no genetic support [1]. A systematic analysis of FDA […]

Meet our team: Jordi Valls

Interview May 6, 2022

Jordi Valls is a Postdoctoral Researcher at MedBioinformatics and experienced in the field of genomic analysis. Dr Valls is currently working on RISKHUNT3R, a European H2020 Project. He is involved in characterising and identifying the adverse effects of chemical compounds on cohorts/target segments depending on their genetic information and variability, through the use of different […]